CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
study is designed to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in adults with complement-mediated kidney...
Phase 2
Madrid, Spain and 24 other locations
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common genetic cause of kidney disease that caus...
Phase 2
Madrid, Spain and 74 other locations
people who have a kidney disease called autosomal dominant polycystic kidney disease (ADPKD)....
Phase 1
Madrid, Spain and 13 other locations
Roxadustat is a licensed medicine to treat anemia in adults with chronic kidney disease (CKD). Anemia is a low level of red blood c...
Phase 3
Madrid, Spain and 46 other locations
tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney...
Phase 2, Phase 3
Madrid, Spain and 330 other locations
with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Part...
Phase 3
Boadilla del Monte, Spain and 561 other locations
to evaluate efficacy, safety and tolerability of treatment with zibotentan/dapagliflozin and dapagliflozin alone in participants with chronic kidney...
Phase 3
Madrid, Spain and 297 other locations
The study evaluates the safety of different doses of a new medicine called NNC0519 0130. It also looks into how the medicine may improve kidney...
Phase 2
Madrid, Spain and 135 other locations
The purpose of this study is to assess the safety, tolerability, pharmacokinetic, and efficacy of surovatamig administered by subcutaneous injection...
Phase 2
Madrid, Spain and 20 other locations
and Tolerability of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in participants with chronic kidney...
Phase 3
Majadahonda, Spain and 744 other locations
Clinical trials
Research sites
Resources
Legal